Main Management ETF Advisors LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Main Management ETF Advisors LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,432 shares of the biotechnology company's stock, valued at approximately $678,000.

A number of other large investors have also added to or reduced their stakes in SRPT. Wellington Management Group LLP increased its holdings in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth $79,425,000. Janus Henderson Group PLC increased its holdings in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company's stock worth $57,356,000 after purchasing an additional 317,277 shares in the last quarter. Finally, Soros Fund Management LLC bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth $25,800,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Robert W. Baird cut their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a research report on Wednesday, November 27th. HC Wainwright lowered their price objective on Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a research report on Tuesday, December 3rd. Finally, Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $175.55.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $1.89 during midday trading on Friday, reaching $128.17. The stock had a trading volume of 619,477 shares, compared to its average volume of 1,329,769. The stock has a market cap of $12.24 billion, a PE ratio of 102.54 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a fifty day simple moving average of $122.71 and a two-hundred day simple moving average of $131.33. Sarepta Therapeutics, Inc. has a 52-week low of $85.61 and a 52-week high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.